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Abstract
Circulating white blood cell (WBC) counts (neutrophils, monocytes, lymphocytes, eosinophils, basophils) differ by ethnicity.
The genetic factors underlying basal WBC traits in Hispanics/Latinos are unknown. We performed a genome-wide association
study of total WBC and differential counts in a large, ethnically diverse US population sample of Hispanics/Latinos
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ascertained by the Hispanic Community Health Study and Study of Latinos (HCHS/SOL). We demonstrate that several previ-
ously known WBC-associated genetic loci (e.g. the African Duffy antigen receptor for chemokines null variant for neutrophil
count) are generalizable to WBC traits in Hispanics/Latinos. We identified and replicated common and rare germ-line variants
at FLT3 (a gene often somatically mutated in leukemia) associated with monocyte count. The common FLT3 variant
rs76428106 has a large allele frequency differential between African and non-African populations. We also identified several
novel genetic loci involving or regulating hematopoietic transcription factors (CEBPE-SLC7A7, CEBPA and CRBN-TRNT1) associ-
ated with basophil count. The minor allele of the CEBPE variant associated with lower basophil count has been previously
associated with Amerindian ancestry and higher risk of acute lymphoblastic leukemia in Hispanics. Together, these data sug-
gest that germline genetic variation affecting transcriptional and signaling pathways that underlie WBC development and
lineage specification can contribute to inter-individual as well as ethnic differences in peripheral blood cell counts (normal
hematopoiesis) in addition to susceptibility to leukemia (malignant hematopoiesis).
Introduction
Total white blood cell (WBC) and differential (neutrophil, mono-
cyte, lymphocyte, eosinophil and basophil) counts are indica-
tors of general health and are influenced by inflammatory,
immune, allergic and hematologic diseases. During normal
hematopoiesis in the bone marrow, WBC production and differ-
entiation are regulated by the coordinated action of hematopoi-
etic growth factor and cytokine signaling, transcriptional
regulation and epigenetic modification of lineage-specific genes
(1). Dysregulation of these pathways leads to abnormal differen-
tiation and proliferation of immature progenitor cells that
underlies the pathogenesis of leukemia and other clonal hema-
tologic disorders (myeloproliferative neoplasms) (2).
Circulating WBC counts are heritable, complex, polygenic
traits (3–5) that exhibit a large degree of inter-individual and
ethnic variation. Genome-wide association studies (GWAS)
have identified approximately 50 genetic loci associated with
WBC traits in individuals of European, Asian and African des-
cent (6–12). Total WBC and neutrophil counts tend to be lower
on average among individuals of African descent compared to
other populations (13). This is partially attributable to the
African-derived Duffy antigen receptor for chemokines (DARC)
‘null’ variant (rs2814778), which is known to confer resistance to
Plasmodium falciparum malaria infection (14,15).
Hispanics/Latinos in the US are a highly heterogeneous eth-
nic group with varied proportions of Amerindian, European and
African ancestry. Data on WBC trait variability in Hispanic/
Latino populations are fairly limited. Despite the greater propor-
tion of African ancestry, Hispanics/Latino on average have been
reported to have higher total WBC and neutrophil counts com-
pared to non-Hispanic whites (16,17). Moreover, certain
acquired or inherited hematologic conditions such as childhood
acute lymphoblastic leukemia (ALL) (18) are more common
among Hispanics/Latinos. Whether previously identified or as-
yet unidentified shared or ethnicity-specific genetic factors con-
tribute to inter-individual WBC trait variability in Hispanics/
Latinos is largely unknown. We therefore performed a GWAS of
total WBC count and WBC subtype counts in a large, ethnically
diverse US sample ascertained by the Hispanic Community
Health Study and Study of Latinos (HCHS/SOL).
Results
Genome-wide association analysis of total WBC and the abso-
lute number of circulating neutrophils, monocytes, lympho-
cytes, eosinophils and basophils was performed in 11 809
Hispanic-/Latino- Americans from HCHS/SOL. Genomic infla-
tion factors ranged from 1.008 (basophils) to 1.034 (neutrophils),
indicating adequate control of population stratification.
Quantile–quantile and Manhattan plots are shown in Figure 1.
Overall, 17 distinct loci, representing 21 combinations of
trait-variant associations, were significantly (P< 5  10 8) or
suggestively (P 1  10 7) associated with total WBC and/or
WBC subtype in the HCHS/SOL Hispanics (Table 1). Of the 21
trait-variant associations, five were with total WBC, four with
neutrophils, one with lymphocytes, five with monocytes, two
with eosinophils and four with basophils. Several of these loci
(DARC, GATA2, HLA-C, CSF3-PSMD3 and SLCO5A1) were associ-
ated with more than one WBC trait.
Generalization of knownWBC-associated loci to HCHS/
SOL Hispanics
The genome-wide significant associations in the HCHS/SOL
Hispanics/Latinos included several known WBC trait-associated
loci (DARC, ITGA4, GATA2, HLA-C; CCDC26-GSDMC; LPAR1 and
CSF3-PSMD3) previously identified in GWAS of European,
African or Asian descent individuals (Table 1). The most
strongly associated variant was the African DARC null variant
rs2814778 for total WBC and neutrophil count.
We formally tested the generalization of previously reported
simple nucleotide polymorphism (SNP) associations with WBC
traits to HCHS/SOL Hispanics/Latinos using a directional false
discovery rate (FDR)-based procedure described under Methods
(Fig. 2; Supplementary Material, Table S1). Of 57 WBC unique
trait-SNP associations previously reported in European
American, African American or Asian descent samples, 38% or
67% showed evidence of generalization to our Hispanic/Latino
discovery sample. On a per trait basis, the replication rate was 1
of 4 loci (25%) for basophils, 6 of 13 loci (46%) for eosinophils, 2
of 2 loci (100%) for lymphocytes, 13 of 16 loci (81%) for mono-
cytes, 4 of 5 loci (80%) for neutrophils and 12 of 17 loci (71%) for
total WBC. When stratified by ancestry of the discovery sample,
the generalization rate was 72% for European Americans, 86%
for African Americans and 73% for Asians.
Our sample size in HCHS/SOL is comparable to that of prior
GWAS of WBC traits performed in other populations
(N¼ 10 000–15 000) (6–12). Nonetheless, our ability to detect gen-
eralization of SNPs in some instances may be limited by statis-
tical power. To address this question, we further assessed the
directional consistency of SNP effect sizes for those SNPs that
failed to generalize by generating a genetic score summing all
trait-increasing alleles for each HCHS/SOL participant. For total
WBC, monocytes, eosinophils and basophils, there were 5, 3, 7
and 3 SNPs, respectively, that failed to generalize. The P-value
for directionally consistent association of the genetic score was
0.34, 0.005, 0.014 and 0.067, respectively, for total WBC,
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monocyte, eosinophil and basophil counts (Supplementary
Material, Table S2). These results suggest that, at least for
monocytes, eosinophils and basophils, low power may contrib-
ute to lack of generalization. Failure to generalize might also
occur because of differences in allele frequency or linkage dis-
equilibrium (LD) patterns for the index SNP in HCHS/SOL com-
pared to the original population.
Discovery and replication of novel WBC-associated loci
Ten of the genome-wide significant WBC trait-locus associ-
ations in HCHS/SOL were not previously reported through
GWAS of quantitative WBC traits (Table 1). These included
LINC01132—LOC101927851 rs3009958 for eosinophils; HAAO
rs114477531 for total WBC; CRBN rs1669340 for basophils;
SLCO5A1 rs2380606 for total WBC and neutrophils; FLT3
rs76428106 for monocytes; JUND rs12973608 for monocytes;
CEBPA rs78744187 for basophils and CPXCR1 rs7882966 for neu-
trophils. In addition to the 10 novel genome-wide significant
loci, a SNP on chr14q11 (rs9743723) had a suggestive association
with basophils (P¼ 4  10 7). The lead SNP rs9743723 is located
downstream of CEBPE, which encodes a hematopoietic tran-
scription factor involved in terminal granulocyte differentiation.
Other CEBPE variants have been associated with risk of
leukemia.
To assess the presence of secondary, independent associ-
ation signals at any of our genome-wide significant regions, we
carried out conditional analyses adjusting for the effect of the
lead variant at each genome-significant WBC trait locus in
HCHS/SOL. The only locus that showed evidence of independ-
ent association signals (P< 5  10 8 following conditional ana-
lysis) was FLT3, where there was evidence of two independent
genome-wide association signals for monocyte count. The lead
variant FLT3 rs76428106 C allele (MAF¼ 1%) was associated with
higher monocyte count (P¼ 8.17  10 11). After conditioning on
the lead variant, the FLT3 rs7327579 A allele (MAF¼ 48%) was
associated with higher monocyte count (P¼ 1.24  10 8) (Fig. 3).
Prior to conditional analysis, the P-value for monocyte associ-
ation for rs7327579 was 3.26  10 6.
On the basis of the HCHS/SOL discovery-stage results and
conditional analysis, we selected 11 variants for follow-up/
replication testing in our Hispanic/Latino validation sample
Table 1. Loci associated with WBC traits in HCHS/SOL discovery sample
Trait SNP Chr:Position Locus Coded/Alt CAF N Beta (SE) p-value AFR AMR ASN EUR
Total WBC rs2814778 1: 159174683 DARC T/C 0.859 11,809 0.1037 (0.0066) 5.68E-56 0.06 0.93 1.00 1.00
Total WBC rs114477531 2: 43146421 HAAO T/C 0.987 11,809 0.0909 (0.0165) 3.60E-08 0.96 0.99 1.00 0.99
Total WBC rs2524079 6: 31242174 HLA-C G/A 0.556 11,809 0.0213 (0.0038) 1.50E-08 0.53 0.52 0.71 0.53
Total WBC rs2380606 8: 70740896 SLCO5A1 T/C 0.491 11,808 0.0240 (0.0039) 8.00E-10 0.11 0.51 0.46 0.51
Total WBC rs2227336 17: 38174855 CSF3-MED24 T/G 0.663 11,809 0.0262 (0.0040) 8.80E-11 0.71 0.66 0.58 0.63
Neutrophil rs2814778 1: 159174683 DARC T/C 0.859 11,809 0.1275 (0.0075) 5.72E-65 0.06 0.93 1.00 1.00
Neutrophil rs2380606 8: 70740896 SLCO5A1 T/C 0.491 11,808 0.0402 (0.0045) 2.22E-19 0.11 0.51 0.46 0.51
Neutrophil rs35272691 17: 38157841 PSMD3-CSF3 T/C 0.593 11,809 0.0297 (0.0045) 4.51E-11 0.90 0.58 0.60 0.64
Neutrophil rs7882966 X: 87982153 CPXCR1 T/C 0.955 11,797 0.0491 (0.0087) 1.81E-08 0.91 0.94 1.00 0.95
Lymphocyte rs2249742 6: 31240721 HLA-C C/T 0.486 11,809 0.0219 (0.0040) 3.70E-08 0.47 0.43 0.49 0.50
Monocyte rs201013030 2: 182324188 ITGA4 T/C 0.447 11,809 0.0132 (0.0015) 7.72E-20 NR NR NR NR
Monocyte rs13277237 8: 130604563 CCDC26-
GSDMC
G/A 0.459 11,808 0.0099 (0.0014) 6.37E-12 0.59 0.49 0.55 0.50
Monocyte rs200243293 9: 113945615 LPAR1 T/TG 0.659 11,809 0.0085 (0.0016) 3.88E-08 0.81 0.62 0.86 0.53
Monocyte rs76428106 13: 28604007 FLT3 T/C 0.990 11,809 20.0497 (0.0076) 8.17E-11 1.00 0.99 1.00 0.99
Monocyte rs12973608 19: 18287220 JUND A/C 0.338 11,809 20.0090 (0.0015) 4.68E-09 0.42 0.36 0.18 0.36
Eosinophil rs3009958 1: 234879890 LINC01132-
IRF2BP2
A/G 0.015 11,789 0.0420 (0.0072) 6.10E-09 0.10 0.01 0.00 0.00
Eosinophil rs13089722 3: 128306757 GATA2 G/A 0.827 11,789 0.0147 (0.0022) 5.40E-11 0.95 0.87 0.64 0.89
Basophil rs1669340 3: 3198380 CRBN1 G/T 0.316 11,789 0.0322 (0.0051) 3.23E-10 0.54 0.30 0.75 0.16
Basophil rs6782812 3: 128317997 GATA2 G/A 0.173 11,789 0.0671 (0.0063) 1.17E-26 0.05 0.12 0.38 0.11
Basophil rs9743723 14: 23577198 CEBPE C/T 0.474 11,789 20.0249 (0.0049) 4.08E-07 0.77 0.46 0.40 0.40
Basophil rs78744187 19: 33754548 CEBPA C/T 0.916 11,789 0.1198 (0.0083) 3.87E-47 0.98 0.91 0.98 0.93
Associations not previously reported are shown in bold.
Coded/Alt, coded, alternative alleles in HCHS/SOL; CAF, coded allele frequency; SE, standard error; 1000 Genomes super-population CAF: AFR, African; AMR, admixed
American; ASN, Asian; EUR, European; NR, not reported.
Figure 2. Generalization of previously reported WBC trait loci to HCHS/SOL. The
top panel contains generalization results for all previously reported loci by trait
(x-axis). The bottom panel contains generalization results for all previously
reported index variants by trait. The total number of previously reported loci or
index variants per trait (y-axis) is shaded dark gray, and the number of general-
ized loci or index variants per trait (r<0.05) is shaded light gray.
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(N¼ 7 200) from the Women’s Health Initiative (WHI) SNP
Health Association Resource (SHARe) project, the Multi-Ethnic
Study of Atherosclerosis (MESA) cohort and the Mount Sinai
BioMe Biobank. These included nine novel genome-wide-signif-
icant associations (rs2380606 was associated with both neutro-
phil count and total WBC), the conditionally independent FLT3
rs7327579 variant for monocyte count, and the suggestive baso-
phil-associated variant CEBPE rs9743723. Nine of ten total var-
iants (except CPXCR1 rs7882966) were available for testing the
11 associations. Of ten associations tested, four were replicated
(P< 0.005 with directional consistency) in the Hispanic/Latino val-
idation sample (Table 2): FLT3 rs7327579 for monocytes, CEBPA
rs78744187 for basophils, CEBPE rs9743723 for basophils and CRBN
rs1669340 for basophils and a fifth variant FLT3 rs76428106 for
monocytes had a suggestive replication (P< 0.009).
While this paper was under review, FLT3 rs76428106 and
CEBPA rs78744187 were reported to be associated with
monocyte-related and basophil-related traits, respectively, in
Europeans in a large UK Biobank meta-analysis (19). In addition,
the minor allele of FLT3 rs76428106 was significantly associated
with higher total WBC and the minor allele of CEBPA rs78744187
was significantly associated with several red blood cell (RBC)
traits [higher RBC count and lower mean corpuscular volume
(MCV) and mean corpuscular hemoglobin (MCH)]. In HCHS/SOL,
although none of these additional blood cell trait associations
reached genome-wide significance, we confirmed that FLT3
rs76428106 was nominally associated with higher total ln(WBC)
(beta¼ 0.043, SE¼ 0.20; P¼ 0.03), while CEBPA rs78744187 was
nominally associated with RBC count (beta¼ 0.042, SE¼ 0.0085;
P¼ 6.6  107), MCV (beta ¼ 0.40, SE¼ 0.13; P¼ 0.0024) and
MCH (beta ¼ 0.14, SE¼ 0.05; P¼ 0.0031).
Functional annotation and overlap of newly identified
FLT3, CEBPA, CEBPE and CRBN-TRNT1 genetic variants
with regulatory elements
FLT3 rs76428106 is in LD (r2¼0.6) with rs79490353, which over-
laps a genomic element enriched for H3K4me1 and H3K27ac en-
hancer histone marks in monocytes (20) and also for H3K4me1,
H3K27ac and H3K4me3 in lymphoblastoid cells (GM12878) and
primary B cells (21). In GM12878 lymphoblastoid cells, the gen-
omic element harboring rs79490353 also overlaps a ChIP-Seq
(chromatin immunoprecipitation followed by sequencing) peak
for the myeloid transcription factor PU.1 (21). RS7327579 is
located within an open chromatin region of a FLT3 intron en-
riched with the enhancer histone mark H3K4me1 that is found
predominantly in monocytes and dendritic cells (20).
Interestingly, the DNase site is hypersensitive in two out of four
BLUEPRINT monocyte donors, further supporting a potential
role for allele-specific differences in FLT3 gene regulation by this
variant. In Europeans and Amerindians, rs7327579 is also in
strong LD (r2¼0.8) with a common FLT3 missense variant
rs1933437 (p.Thr227Met) located in the second Ig-like domain of
the extracellular ligand-binding region. This amino acid substi-
tution is predicted to be likely damaging (22).
The CEBPA rs78744187 lead variant is a strong functional
candidate due to its location in a K562 myeloid leukemia cell
line, CD34þ cell and monocyte DNaseI site and active enhancer
region that binds several hematopoietic transcription factors
(CEBPb, GATA-2 and TAL-1) in a blood cell-specific manner
(20,22). Another myeloid-specific regulatory element (enriched
for H3K4me1, H3K4me3 and H3K27ac marks in monocytes,
macrophages and neutrophils) harbors two additional LD proxy
variants, rs958483 and rs73926283.
The lead SNP CEBPE rs9743723 is in LD with several candi-
date functional SNPs located within promoter or enhancer his-
tone marks and some of these variants have been suggested to
influence CEBPE expression (23,24). For example, the LD proxy
variant rs10143875 is located within a transcribed CEBPE enhan-
cer and is bound in vitro by several transcription factors includ-
ing PU.1 and Jun in granulocytes and monocytes (20,22). It is
noteworthy that rs10143875 putatively alters binding motifs for
BCL6B and STAT5A; the latter transcription factor has been
Figure 3. LocusZoom plots showing two independent association signals for
monocyte count at the FLT3 locus. The Panel (a) contains a LocusZoom plot of the
FLT3 locus centered on our top variant, rs76428106 (imputed), indicated by a pur-
ple triangle. The Panel (b) contains a LocusZoom plot of the FLT3 locus centered
on rs7327579, the top variant after conditional analysis on rs76428106. rs7327579
is genotyped and hence represented by a purple diamond. The LD estimates
derived from the HCHS/SOL study samples with respect to the top variant and
the other variants in the window are color-coded by correlation category accord-
ing to the scale in the upper right of each panel. Imputed variants are denoted by
an x, and genotyped variants are denoted by a filled circle. Recombination hot-
spots from HapMap are indicated by vertical blue peaks. Genes within the region
of interest are listed by chromosomal position beneath the x-axis. The horizontal
line indicates the significance threshold P-value, 5  108.
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implicated in basophil and mast cell lineage specification and
differentiation (25). Another proxy SNP, rs2239635, was reported
to disrupt binding of the hematopoietic transcriptional repres-
sor Ikaros, which is a negative regulator of basophil production
(26).
The chromosome 3p26 association signal for higher basophil
count encompasses several non-coding variants which are cis-
eQTL for CRBN and TRNT1 in whole blood. The lead CRBN SNP
rs1669340 and several proxy variants are located within blood
cell epigenomic promoter or enhancer marks (20,22).
Discussion
In a GWAS of nearly 12 000 US Hispanics/Latinos, we discovered
and replicated several WBC trait loci. These include two inde-
pendently associated FLT3 signals for monocyte count, two
CCAAT/enhancer binding proteins (CEBPE and CEBPA) for baso-
phil count and CRBN for basophil count. The two distinct FLT3
variants rs76428106 and rs7327579 are low-frequency and
common, respectively, and have different allele frequencies in
different ancestry groups. We also demonstrated the generaliz-
ability to Hispanics/Latinos of the majority of WBC trait loci pre-
viously identified in GWAS of European, African or Asian
ancestry. The new FLT3, CEBPE, CEBPA and CRBN loci suggest
that hematopoiesis-related genes that are grossly altered in ma-
lignant hematopoiesis can additionally harbor genetic variants
with smaller effect magnitudes that influence circulating levels
of WBC subtypes in individuals with no known hematological
cancers.
FLT3 variants associated with monocyte count
The lead FLT3 variant rs76428106 (associated with higher mono-
cyte count) is intronic and has an allele frequency of 1% in
European and Amerindian populations but is monomorphic in
African and Asian 1000 Genomes reference populations. After
conditioning on the lead FLT3 variant rs76428106, a second FLT3
variant (rs7327579) was independently associated with higher
monocyte count. rs7327579 is common (MAF¼ 48%), but has a
large allele frequency differential between African (A allele fre-
quency¼ 14%) and non-African populations (A allele frequency
54% in Amerindian, 53% in European, 64% in South Asian and
70% in East Asian 1000 Genomes superpopulations).
FLT3 is a receptor tyrosine kinase that regulates early hem-
atopoiesis (27) and is frequently mutated in hematologic malig-
nancies and is an important prognostic factor and therapeutic
target for acute myeloid leukemia (AML) (28,29). FLT3 is ex-
pressed not only on early myeloid progenitors, but also on
monocytes and thereby promotes monocyte/macrophage prolif-
eration and differentiation as well as development and activa-
tion of monocyte-derived dendritic cells (30,31). The two
monocyte count-associated FLT3 variants identified in individ-
uals from HCHS/SOL with no know hematological cancers are
distinct from the well-characterized activating FLT3 somatic
mutations frequently observed in AML. The FLT3 leukemic mu-
tations generally consist of internal tandem duplications and
point mutations involving, respectively, the FLT3 juxtamem-
brane domain and tyrosine kinase domain, and lead to constitu-
tive activation of the FLT3 receptor and dysregulated
downstream signaling pathways and ligand-independent mye-
loid proliferation (29). The FLT3 monocyte count-associated
variants identified in HCHS/SOL likely have subtler effects on
later stages of granulocyte/monocyte lineage specification.T
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Given the poorer prognosis of AML among African Americans
compared to whites (32), additional study of FLT3 variants in
AML outcomes may be warranted.
CEBPA and basophil count
The basophil association signal on chr19q13.11 is located ap-
proximately 30 kb downstream from CEBPA, which encodes C/
EBPa, a transcription factor that plays an essential role in mye-
loid differentiation and specification of neutrophil, monocyte
and basophil lineage fates (33). The timing of expression of
GATA2 and CEBPA are important for myeloid lineage fate,
including the production and differentiation of basophils and
mast cells (34). The minor allele of the lead SNP associated with
lower basophil count (rs78744187, T allele frequency¼ 8.4%) is
3-fold more common in Amerindians and Europeans than
Africans and Asians.
Highly penetrant germline mutations and acquired somatic
mutations of CEBPA each contribute to abnormal WBC matur-
ation and the development of AML (25,26). Since the basophil-
associated candidate functional SNP rs73926283 disrupts a bind-
ing site for the ZFX hematopoietic proto-oncogene, further as-
sessment of this basophil count-associated variant may be
warranted in the context of leukemia disease progression or
treatment resistance (35).
CEBPE and basophil count
The region on chr14q11.2 associated with basophil count is
localized to a 13 kb LD block downstream of CEBPE, encoding
CCAAT/enhancer-binding protein e, another CEBP family tran-
scription factor involved in myelopoiesis and terminal granulo-
cyte differentiation (36–38). The minor allele of the basophil-
lowering HCHS/SOL index SNP rs9743723 (C, allele fre-
quency¼ 47%) is also in moderate LD with a set of CEBPE SNPs
increased susceptibility to childhood ALL (39,40). The higher in-
cidence of ALL and poorer outcomes among Hispanic children
have been attributed in part to genetic risk factors associated
with Amerindian ancestry (41,42). It is interesting to note that
the myeloid enhancer containing rs22239630 is bound by Pol II
in NB4 cells (an acute promyelocytic leukemia cell line). The
same SNP is predicted to disrupt a putative binding site for ZFX,
a transcription factor that maintains a stem/progenitor-like im-
mature phenotype and proliferative capacity of leukemia cells
in AML, CML and T-ALL (43). Given the role of CEBPe as a sup-
pressor of myeloid leukemogenesis, the newly identified
basophil-associated CEBPE variant may have additional clinical
and therapeutic implications for hematologic cancers (44,45).
CRBN and basophil count
The chromosome 3p26 association signal for higher basophil
count encompasses several non-coding variants of CRBN and
TRNT1. Loss-of-function mutations in TRNT1 result in sidero-
blastic anemia with B-cell immunodeficiency, periodic fevers
and developmental delay (46). CRBN (cereblon), a component of
the substrate receptor for an E3 ubiquitin ligase, was recently
identified as the molecular target of lenalidomide (LEN), a thal-
idomide derivative and immunomodulatory drug used to treat
hematologic malignancies such as multiple myeloma and 5q-
deletion-associated myelodysplastic syndrome (47,48). LEN in-
hibits ubiquitination of endogenous CRBN substrates and also
alters ligase substrate specificity to target new proteins for
degradation including IKZF1, a transcription factor important
for basophil development and a tumor suppressor for leukemia
(49).
Other WBC loci that generalize to Hispanics/Latinos and
implications for WBC/immune-related diseases
Other genome-wide significant associations in the HCHS/SOL
included several known WBC trait-associated loci previously
identified in GWAS of European-, African- or Asian-descent in-
dividuals containing genes involved in WBC production, migra-
tion or clearance from the circulation (see Table 1). Several of
these loci may have implications for ethnic or racial disparities
in chronic disease health outcomes. For example, the DARC-
null rs2814778 genotype has been under selection among
Africans as a receptor for Plasmodium vivax malaria and is also a
major determinant for ethnic neutropenia, which could have
impact on the pathogenesis of diseases such as HIV or minority
participant eligibility in cancer clinical trials (due to exclusion
on the basis of low blood counts) (13). Other WBC-associated
variants are associated with inflammatory and autoimmune
diseases such as GSDMC with inflammatory bowel disease (50),
CSF3-PSMD3 with asthma (51), and HLA-C with psoriasis (52),
rheumatoid arthritis (53) and Crohn’s disease (50). The GATA2
variant associated with basophil and eosinophil counts in
European Americans and Hispanics/Latinos may have implica-
tions for the occurrence of hematopoietic disorders (54) as well
as allergic diseases such as asthma (55), which varies in preva-
lence and morbidity among Hispanic/Latino ethnic subgroups
in the United States (56).
Conclusions
In summary, we provide evidence for considerable shared gen-
etic architecture of WBC traits between Hispanics/Latinos and
other ethnic groups. We identified several novel WBC trait loci,
including variants of FLT3 associated with monocyte count, and
variants of three known regulators of granulocyte and basophil
differentiation (CEBPE, CEBPA and CRBN) associated with baso-
phil count. All four of these hematopoiesis-related genes are
often grossly altered in hematologic malignancies. Thus, gen-
etic variants with subtler regulatory effects on the same genes
may influence circulating levels of WBC subtypes during normal
hematopoiesis. Further studies are warranted to assess whether
any of these basophil-associated genetic variants are associated
with disease susceptibility or outcomes related to leukemia and
myeloproliferative neoplasms.
Materials and Methods
HCHS/SOL population
The HCHS/SOL is a community-based cohort study of 16 415
self-identified Hispanic/Latino persons aged 18–74 years se-
lected from households in predefined census-block groups from
four US field centers (Chicago, Miami, the Bronx and San Diego).
Participants self-identified as having a Hispanic/Latino back-
ground; the largest groups were Central American (n¼ 1 730),
Cuban (n¼ 2 348), Dominican (n¼ 1 460), Mexican (n¼ 6 471),
Puerto Rican (n¼ 2 728) and South American (n¼ 1 068). The
sample design and cohort selection have been previously
described (57). HCHS/SOL participants were recruited between
2008 and 2011 and underwent a baseline clinical examination
(58) including biological, behavioral and sociodemographic
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assessments. The study was approved by the institutional re-
view boards at each field center, where all subjects gave written
informed consent.
Measurement of WBC and exclusion criteria
in HCHS/SOL
Total WBC and differential counts were measured in EDTA
whole blood obtained at the baseline examination using a
Sysmex XE-2100 instrument (Sysmex America) at the University
of Minnesota according to national and international standards
and procedures. Individuals pregnant at the time of blood draw;
those with>5% circulating blasts or immature cells, end-stage
renal disease or any hematologic malignancy; and those
undergoing chemotherapy for solid tumors were excluded from
our analyses.
Genotyping, imputation and quality control
in HCHS/SOL
Consenting HCHS/SOL subjects were genotyped at Illumina on
the HCHS/SOL custom 15041502 B3 array. The custom array
comprised the Illumina Omni 2.5M array (HumanOmni2.5-
8v.1-1) plus 150 000 custom SNPs including ancestry-
informative markers, known GWAS hits and drug absorption,
distribution, metabolism and excretion (ADME) markers, and
SNPs selected from the CLM (Colombian in Medellin,
Colombia), MXL (Mexican Ancestry in Los Angeles, California)
and PUR (Puerto Rican in Puerto Rico) samples in the 1000
Genomes phase 1 data to capture a greater amount of
Amerindian genetic variation.
We applied standardized quality-assurance and quality-
control (QA/QC) methods (59) to generate recommended SNP-
and sample-level quality filters. Samples were checked for sex
discrepancies, gross chromosomal anomalies, relatedness and
population structure, missing call rates, batch effects and
duplicate-sample discordance. After excluding participants who
were ineligible or missing phenotype or genotype data, 11 809
study participants were available for analysis. SNPs were
checked for Hardy–Weinberg equilibrium, minor allele fre-
quency (MAF), duplicate-probe discordance, Mendelian errors
and missing call rate. A total of 2 232 944 SNPs passed filters for
both quality and informativeness (polymorphic and undupli-
cated) and were carried forward for imputation and down-
stream association analyses.
Genome-wide imputation in HCHS/SOL was carried out
using the full, cosmopolitan 1000 Genomes Project phase 1 ref-
erence panel (n¼ 1 092) (60), as previously described (61). Briefly,
genotypes were first pre-phased with SHAPEIT2 (v.2.r644) and
then imputed with IMPUTE2 (v.2.3.0) (62,63). Overall imputation
quality was assessed by calculating ‘oevar’ (the ratio of the
observed variance of imputed dosages to the expected binomial
variance) using the MaCH imputation software (64) and by
examination of the distribution of imputation quality metrics
from the IMPUTE2 internal masking experiments. We per-
formed downstream association analyses on observed variants
passing quality filters and all imputed variants (a total
of 27 887 661 variants). Results were then filtered on the basis
of imputation quality (oevar> 0.3) and allele frequency
(MAF> 1%).
Linear mixed-effect model for association testing in
HCHS/SOL
We analyzed WBC phenotypes by using linear mixed-effect
models (LMMs) to account for the correlations due to genetic re-
latedness (kinship), shared household and block group between
individuals. All analyses were adjusted for sex, age, five princi-
pal components (PCs), recruitment center, smoking status, log
of sampling weights (to prevent potential selection bias due to
the sampling scheme) and genetic-analysis group (a six-level
categorical variable derived from genetic data and self-
identified background) (61). To approximate normal distribution
of the model’s residuals, the outcomes were either log-
transformed (WBC, lymphocytes) or log transformed after add-
ition of the constant 1 (neutrophils, monocytes, eosinophils,
basophils). For basophils, we also performed a sensitivity
analyses due to the large numbers of zero values due to round-
ing. In the sensitivity analysis, we dichotomized basophil count
to 0 vs. non-zero, and we applied a score test based on a logis-
tic mixed model, with the same fixed and random effects as
before (65).
Replication of discovery loci in independent Hispanic/
Latino samples
To replicate association findings in Hispanic/Latino samples, we
used 1000 Genomes imputed GWAS data available in three add-
itional Hispanics/Latinos samples, including up to 3 454 from
the WHI SHARe project (66); 782 from the MESA cohort (67,68)
and 2 854 from Mount Sinai BioMe Biobank (69). WHI-SHARe
and MESA participants were genotyped with the Affymetrix
6.0 chip, and imputation was performed with MaCH (64).
BioMe participants were genotyped with the Illumina
HumanOmniExpressExome-8 v.1.0 chip, and imputation was
performed with IMPUTE2 (62,63) in 1000 Genomes phase 1 data
(March 2012 v.3). Association testing for typed or imputed SNPs
was performed by linear regression of log-transformed WBC
count adjusted for age, sex and PCs. Meta-analysis of results
from the three replication cohorts for total WBC and WBC sub-
types was performed with the inverse-variance-weighted
method implemented in METAL (70). To declare significance for
replicated WBC loci, we required that (a) the directionality of ef-
fect was similar across the discovery and replication phases
and (b) the replication P-value met the Bonferroni corrected cri-
teria for multiple testing (P-value<0.05/10¼ 0.005).
Generalization in HCHS/SOL
We performed generalization analysis for WBC-associated SNPs
previously reported in GWASs of other populations, including
those of European, African and Japanese ancestry (2,6–11). In
testing for generalization we controlled the directional FDR of
the generalization null hypotheses at a threshold of 0.05 (71, in
press). The generalization null hypothesis states that the effect
does not exist in either the discovery study nor in HCHS/SOL
and is rejected if there is enough evidence that a SNP affects the
outcome, with the same direction of effect, in both the discov-
ery study and HCHS/SOL. A SNP was generalized if its r
value<0.05.
Functional annotation of discovery loci
We interrogated the WBC-associated loci to determine whether
the identified non-coding SNPs and indels and correlated proxy
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variants (r20.5, calculated in the HCHS/SOL discovery popula-
tion) were positioned within predicted regulatory regions,
namely enhancers and promoters and the nearest biologically
plausible gene or genes. These regulatory regions were identi-
fied on the basis of the enrichment of various histone-
modification and ChIP-seq signals in WBCs (granulocytes,
lymphocytes, monocytes, dendritic cells) and bone marrow pre-
cursor cells from the Blueprint project (20). A genomic element
enriched with the histone H3K4me1 signal was categorized as
an enhancer, whereas a genomic element enriched with the
histone H3K4me3 signal was categorized as a promoter. SNPs or
indels belonging to either promoter or enhancer categories that
overlap a DNase I hypersensitive site (a general biochemical fea-
ture of regulatory regions) in blood or bone marrow-derived
cells were prioritized as putatively functional variants. We also
reported whether a given SNP overlaps with any transcription
factor ChIP-seq peaks (72). Moreover, because related cell types
can share similar regulatory regions, we additionally reported
supplementary annotation by using data on other myeloid lin-
eage cells and GM12878 lymphoblastoid cells (72). To identify
the motifs disrupted by alleles, we utilized HaploReg (v4) (21)
and the JASPAR motif database (73).
Supplementary Material
Supplementary Material is available at HMG online.
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